Sun Pharma Advanced Research Company (SPARC) Q4 25/26 earnings summary

Executive summary

• Audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 were approved, with auditors expressing an unmodified opinion on both sets of results.

• A significant one-time income was recognized from the sale of a USFDA Priority Review Voucher (PRV) for Sezaby®, boosting annual results.

Financial highlights

• Standalone total income for FY26 was ₹189,000 lakhs, up sharply from ₹7,356 lakhs in FY25, mainly due to PRV income.

• Standalone profit before tax for FY26 was ₹155,213 lakhs, compared to a loss of ₹34,522 lakhs in FY25.

• Consolidated total income for FY26 was ₹189,012 lakhs, with profit before tax at ₹155,301 lakhs, versus a loss of ₹34,278 lakhs in FY25.

• Basic and diluted EPS for FY26 was ₹47.83 (standalone) and ₹47.86 (consolidated), compared to a loss per share of ₹10.64 and ₹10.55, respectively, in FY25.

Outlook and guidance

• The company continues to monitor the impact of India's new labour codes on employee benefits and will account for further impacts as required.